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CLOSING THE REGULATORY GAP IN PHYSICIAN COMPOUNDING:
HOW NEW JERSEY CAN EFFECTIVELY REGULATE DRUG
COMPOUNDING IN THE NON‐PHARMACY SETTING
Deanna M. Digori*
I. INTRODUCTION
Drug compounding is an important part of the healthcare system
and affords patients access to custom prescription medications that best
fit their individualized needs.1 There are a variety of reasons why
certain standardized Food and Drug Administration (“FDA”) approved
drugs may need to be modified for specific patients, including a change
in dosage, concentration, method of delivery, or to accommodate certain
allergies.2 To best fit these needs, drugs may be compounded by
pharmacists in special compounding pharmacies, or even by physicians
in their offices.3 Interestingly, the regulations governing these
compounding processes are very different.4 The FDA articulated several
broad guidelines to direct the compounding of medications in general,
but state organizations enforce their own compounding regulations.5 A
state’s board of pharmacy typically creates regulations to govern
compounding in pharmacies; however, compounding done by
physicians in their offices is much less regulated, if at all.6 State
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1 See Compounding and the FDA: Questions and Answers, U.S. FOOD AND DRUG ADMIN.,
https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fdaquestions-and-answers [hereinafter Compounding and the FDA] (last updated June 21,
2018); Pew Charitable Trusts et al., State Oversight of Drug Compounding, 4 (Feb. 2018),
https://www.pewtrusts.org/media/assets/2018/02/drug_safety_assesment_web.pdf
[hereinafter State Oversight].
2 Compounding and the FDA, supra note 1; See generally State Oversight, supra note
1.
3 State Oversight, supra note 1, at 1.
4 See generally State Oversight, supra note 1.
5 See State Oversight, supra note 1, at 4-5, 16; Joanne S. Eglovitch, The FDA Aims To
Strike Balance On Inspecting Physicians Who Compound, PINK SHEET (Aug. 8, 2019).
6 National Reports Raise Questions About Oversight of Drug Compounding in
Physicians’ Offices, 46 NEWSL. OF THE NAT. ASSOC. OF BDS. OF PHARMACY 3, 6-7 (Mar. 2017),
https://nabp.pharmacy/wp-
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pharmacy boards do not have jurisdiction over physicians and the
board’s regulations regarding medical compounding do not reach far
enough to cover physicians.7 Additionally, state medical boards govern
a physician’s practice, but rarely enact or enforce any regulations
regarding drug compounding.8 This legislative gap recently came to
light when numerous public health crises arose relating to drug
compounding.9 These crises brought legislators and regulatory bodies
together to establish more stringent regulations to create safer products
for the consumer.10 In order for New Jersey to safeguard its residents
while still providing efficient access to the customized medications
residents need, state legislators must make changes to the compounding
regulatory process done inside physicians’ offices.
Part II of this comment will examine the history of drug
compounding, the benefits and risks associated with compounded
medications, and the current status of regulations regarding
compounding both in New Jersey and across the country. Part II will
also detail the meningitis crisis of 2012 which highlighted the dangers
of drug compounding and pushed regulators across the country to make
a change to drug compounding regulations.11 Part III of this comment
will outline the different pathways New Jersey can take to change
regulations regarding physician in-office compounding to promote a
more perfect balance between efficiency of care and safety of patients.
Part III begins with an analysis of the new regulations in Ohio, which
were promulgated in 2017,12 and then considers current FDA and
United States Pharmacopeia (“USP”) concerns. This comment will argue
New Jersey would be best served by a new legislative and regulatory
approach guided by the principles in the Ohio regulations. This new
approach should stimulate the use of the more heavily regulated 503B
outsourcing facilities by adopting stricter regulations on 503A facilities,
content/uploads/2016/07/Innovations_March__2017_Final.pdf [hereinafter National
Reports Raise Questions].
7 National Reports Raise Questions, supra note 6, at 6.
8 National Reports Raise Questions, supra note 6, at 6, 7.
9 Stacey L. Worthy, The Compounding Conundrum: How Insufficient Delineation of
Regulatory Responsibility Has Created a Need for State and Federal Compounding Drug
Law Reform, 72 FOOD DRUG L. J. 506, 521 (2017).
10 State Oversight, supra note 1, at 4.
11 State Oversight, supra note 1, at 4.
12 OHIO REV. CODE. ANN. § 4729.541(c)-(d) (LexisNexis 2017); Terminal Distributor
Requirements for Prescribers Possessing Compounded Drugs or Engaging in Drug
Compounding,
STATE
OF
OHIO
BD.
OF
PHARM.
(Feb.
11,
2017)
https://www.pharmacy.ohio.gov/Documents/Licensing/TDDD/General/Terminal%2
0Distributor%20Requirements%20for%20Prescribers%20Possessing%20Compound
ed%20Drugs%20or%20Engaging%20in%20Drug%20Compounding.pdf.
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and by incentivizing their usage through tax breaks.13 In addition to
these regulatory measures, to best serve New Jersey and its residents,
this comment will also propose that New Jersey should create a hybrid
committee comprised of members from both the New Jersey Board of
Pharmacy and the New Jersey Board of Medical Examiners. This
dynamic group, after intense collaborative research, can erect a
comprehensive and effective set of regulations for physicians who
choose to compound medications for patients in their own offices. Part
IV of the comment will conclude with the different proposals outlined
throughout the comment and once again highlight the need for and
importance of this regulation.
II. BACKGROUND
A. What is a Compounded Medication?
Today, large pharmaceutical companies manufacture mass
quantities of most medications available to consumers in the United
States.14 Physicians or other healthcare providers prescribe these
drugs, and then pharmacists in traditional pharmacies dispense the
drugs to patients.15 In contrast to manufactured medications,
compounded medications are modified drugs that physicians or
pharmacists make in small doses specifically for an individual patient.16
The USP, the only independent, nongovernmental pharmacopeia17 in
the world, defines compounding as “the preparation, mixing,
assembling, altering, packaging, and labeling of a drug, drug-delivery
device, or device in accordance with a licensed practitioner’s
prescription
...
based
on
the
practitioner/patient/pharmacist/compounder relationship in the
course of professional practice.”18 Stated more simply, a physician or a
13 See generally infra note 52 (delineating the facilities that fall under 503A
regulations.).
14 Burt’s – Medicine, Understanding the Difference Between Compounding and
Pharmaceutical
Manufacturing,
BURT’S
RX
(Jan.
6,
2018),
https://burtsrx.com/difference-compounding-pharmaceutical-manufacturing/.
15 See id.
16 Id.
17 A pharmacopeia is a collection of uniform pharmaceutical standards comprised
of requirements regarding the quality of medicinal products, the substances used to
manufacture them, and quality control methods; See generally J. Mark Wiggins & Joseph
A. Albanese, A Brief History of Pharmacopoeias: A Global Perspective, BIOPHARM INT’L
(Sept. 15, 2019).
18 Frequently Asked Questions About Pharmaceutical Compounding, AM. PHARMACISTS
ASS’N, https://www.pharmacist.com/frequently-asked-questions-aboutpharmaceutical-compounding [hereinafter Frequently Asked Questions] (last visited
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pharmacist mixes and prepares compounded medications for a certain
individual based on a prescription from a physician when no FDAapproved medication fits a patient’s precise needs.19 Often described as
both an art and a science, this process allows patients to obtain
individualized care tailored specifically to them.20
Specific needs that can be served by a compounded medication
include changes in dosage or method of delivery as well as changes to
accommodate certain allergies.21 Changes in dosage and method of
delivery are most common when physicians treat children, the elderly,
and patients with other special healthcare needs.22 For example, many
children are unable to swallow oral tablet medications; this poses
problems if a physician decides the child requires a medication that is
only commercially manufactured in an oral tablet form.23 However,
drug compounding addresses this issue by allowing pharmacists or
physicians to mix the same active ingredients of the oral tablet into a
liquid or suppository in order for the child to ingest the medication.24
This process may also be used for the elderly who may be unable or
unwilling to take oral capsule medications.25
Additionally, compounded medications provide a unique solution
for patients with various allergies.26 Mass manufactured drugs are
created to cause reactions in as few people as possible; however, there
are some medications that include various allergens like lactose, gluten,
or certain dyes.27 Compounding allows for a pharmacist or physician to

Jan. 16, 2021). See also Review of World Pharmacopoeias 3 (WHO, Working Document
QAS/12.512/Rev.1 (Mar. 2013),
https://www.who.int/medicines/areas/quality_safety/quality_assurance/resources/I
nternationalMeetingWorldPharmacopoeias_QAS13-512Rev1_25032013.pdf (defining
a pharmacopoeia as “a legally binding collection, prepared by a national or regional
authority, of standards and quality specifications for medicines used in that country or
region.”).
19 Frequently Asked Questions, supra note 18.
20 Frequently Asked Questions, supra note 18.
21 Compounding and the FDA, supra note 1.
22 See Tricia Heitman, A. J. Day & August S. Bassani, Pediatric Compounding
Pharmacy: Taking on the Responsibility of Providing Quality Customized Prescriptions,
CHILDREN (BASEL) 1, 5 (May 4, 2019), https://www.ncbi.nlm.nih.gov /pmc/articles/
PMC6560512/.
23 Id. at 1.
24 Id.
25 Compounding and the FDA, supra note 1.
26 Burt’s – Compounding Six Medical Situations That Call for Compounded
Medications, BURT’S RX (July 21, 2017), https://burtsrx.com/6-medical-situationscompounded-medications/.
27 Patients with Allergies Look to Compounding Pharmacies for Medication, ARENA
DISTRICT PHARM. (Nov. 25, 2017), https://www.arenadistrictpharmacycolumbus.com/
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create an individualized version of that medication by either removing
the additive and leaving only the active, essential ingredients; they can
also add an antihistamine to the drug in order to combat an allergy.28
Without compounding, these patients would not be able to get the
medications they need, or, if the medication was particularly
indispensable to their health, the patient would have to suffer the
adverse consequences due to their allergy.29
Compounded medications are created when the exact strength of a
drug “may not be commercially available” or when a patient needs “a
drug that is currently in shortage” or when such drug has been
discontinued for whatever reason.30 In addition to the uses above,
compounded medications are also used to treat hormone-related
conditions, pain, and skin issues.31 Most prescriptions for compounded
medications
come
from
dermatologists,
pain
specialists,
32
endocrinologists, and gastroenterologists.
There have been
significant increases in the dermatological compounds such as sprays,
gels, foams, and ointments.33 Usually pharmacists, or dermatologists
themselves, compound these gels to contain one or more anesthetic,
analgesic, sedative, antidepressant, anti-seizure or muscle relaxant
drugs that are used to treat pain.34
blog/26848/Patients-with-Allergies-Look-to-Compounding-Pharmacies-forMedication/ [hereinafter Patients with Allergies].
28 Id.
29 Id.
30 Frequently Asked Questions, supra note 18.
31 Ronilee Shye, What Are Compounded Medications?, GOODRX (last visited Jan. 16,
2021), https://www.goodrx.com/blog/what-are-compounded-medications/.
32 Aamir Hussain & Diana Bolotin, The Drug Compounding Debate and its Importance
to Dermatologists,
DERMATOLOGIST
(last
visited
Jan.
16,
2021),
https://www.thedermatologist.com/article/drug-compounding-debate-and-its-importancedermatologists; Ronilee Shye, What Are Compounded Medications?, GOODRX (last visited
Dec. 12, 2020), https://www.goodrx.com/blog/what-are-compounded-medications/.
33 Compounding Pharmacies Market to Hit $14 Billion by 2026, PR NEWSWIRE (last
visited Dec. 12, 2020), https://www.prnewswire.com/news-releases/compoundingpharmacies-market-to-hit-14-billion-by-2026-global-market-insights-inc301073406.html; See also Research Pushes Back on Benefits of Compounded Topical Pain
Creams,
JOHNS
HOPKINS
MED.
(Feb.
5,
2019),
https://www.hopkinsmedicine.org/news/newsroom/news-releases/researchpushes-back-on-benefits-of-compounded-topical-pain-creams.
34 Research Pushes Back on Benefits of Compounded Topical Pain Creams, JOHNS
HOPKINS
MED.
(Feb.
5,
2019),
https://www.hopkinsmedicine.org/news/newsroom/news-releases/researchpushes-back-on-benefits-of-compounded-topical-pain-creams; However, there is a
growing body of research that suggests these topical creams have no scientific benefit,
and are not nearly as effective as the oral equivalents of these medications. This
comment will not discuss the effectiveness of these drugs and will instead focus on their
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It is important to note that the FDA itself does not regulate the
approval process of compounded drugs.35 The FDA seeks control over
compounded medications by enacting federal regulations that must be
enforced by state regulatory agencies.36 Although FDA regulations
surround and attempt to regulate compounded drugs, these drugs are
not subject to the same quality assurance standards as are massmanufactured medications.37
B. Who Can Compound Medications?
Those engaged in human drug compounding can be divided into
two distinct categories: traditional and non-traditional compounders.38
Traditional compounders consist of pharmacists and physicians.39 The
most common compounding is done by licensed pharmacists in
compounding pharmacies.40 Currently, about 7,500 compounding
pharmacies in the United States specialize in advanced compounding
services.41 Of these compounding pharmacies, approximately 3,000 of
them produce sterile products that must be made under stricter
Injections or infusions
standards than non-sterile products.42
traditionally use sterile compounds.43
Typically suspensions,
ointments, creams, or capsules use non-sterile products.44 In addition
to pharmacists, physicians may also compound drugs in their offices.45
The scope of physician in-office compounding is quite unknown and the
National Association of Boards of Pharmacy has opined that the number

prevalence in the field. This comment will also address how this practice factors into
physician in-office compounding and will highlight the need for new regulations.
35 Compounding and the FDA, supra note 1; This point will be explained in greater
detail below.
36 See Compounding and the FDA, supra note 1.
37 Compounding and the FDA, supra note 1.
38 See State Regulation of Compounding Pharmacies, NAT’L CONF. OF STATE LEGS. (Oct.
1, 2014), http://www.ncsl.org/research/health/regulating-compoundingpharmacies.aspx; see also Drug Quality and Security Act, H.R. 3204, 113th Cong. (20132014).
39 Frequently Asked Questions, supra note 18.
40 Frequently Asked Questions, supra note 18.
41 Daniel J. DeNoon, What Are Compounding Pharmacies? Meningitis Outbreak From
Compounded Drug Raises Questions Over Pharmacies, WEBMD (Oct. 10, 2012),
https://www.webmd.com/brain/news/20121010/what-are-compoundingpharmacies#1.
42 Id.
43 Sterile vs Non‐Sterile Compounding Pharmacies, RENUE PHARMACY (last visited Oct.
3, 2020) https://renuerx.com/sterile-vs-non-sterile-compounding-pharmacies/.
44 Id.
45 National Reports Raise Questions, supra note 6.
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of physician-compounders varies widely by specialty.46 Physicians who
are general practitioners may perform no in-office compounding, while
other more specialized physicians (like allergists and dermatologists)
may treat hundreds of patients with compounded medication.47
Specialists like allergists, dermatologists, immunologists, oncologists,
ophthalmologists and rheumatologists are most likely to engage in inoffice compounding, and therefore, are most likely to be affected by any
new compounding regulations.48
In 2013, through the Drug Quality and Security Act (“DQSA”),
Congress created a new regulatory category of drugs compounders
called “outsourcing facilities.”49 DQSA established a new section of the
Federal Food, Drug, and Cosmetic Act (“FDCA”), Section 503B, that set
forth regulations for these facilities to compound drugs in compliance
with the FDA.50 The FDA categorizes these facilities as being nontraditional compounders because their drugs need only be compounded
under the supervision of a licensed pharmacist.51 Additionally,
outsourcing facilities are able to produce large batches of popular,
compounded drugs with or without a prescription to be sold to
healthcare facilities because those drugs are non-patient specific.52
Drugs compounded by facilities in compliance with 503B qualify for
exemptions from some FDA approval requirements, including drug
approval processes, labeling requirements, and supply chain tracking
requirements.53 However, this registration does not excuse outsourcing
facilities from current good manufacturing process (“CGMP”)
requirements.54 Outsourcing facilities registered with the FDA are also
subject to inspection by the FDA according to a risk-based schedule and
must also report to the FDA adverse events that occur at the facility.55

National Reports Raise Questions, supra note 6.
National Reports Raise Questions, supra note 6.
48 National Reports Raise Questions, supra note 6.
49 Center for Drug Evaluation and Research: Outsourcing Facility Information, U.S.
FOOD AND DRUG ADMIN. 2 (Sept. 2017), http://www.fda.gov/media/107569/download.
50 Id.
51 Id.
52 Compounding Pharmacies: Understanding 503A vs. 503B Designations and Why It
Matters,
WELLS
PHARMACY
NETWORK
(last
visited
Oct.
3,
2020),
http://www.wellsrx.com/503a-vs-503b-compounding-pharmacies/
[hereinafter
Understanding 503A vs. 503B].
53 Id.; Joanna Shepherd, Regulatory Gaps in Drug Compounding: Implications for
Patient Safety, Innovation, and Fraud, 68 DEPAUL L. REV. 385, 396 (2019).
54 Understanding 503A vs. 503B, supra note 52.
55 Center for Drug Evaluation and Research: Outsourcing Facility Information, U.S.
FOOD AND DRUG ADMIN. 4 (Sept. 2017), http://www.fda.gov/media/107569/download.
46
47
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C. What are the Benefits and Risks Associated with
Compounded Medications?
Compounding drugs has been a cornerstone of the pharmaceutical
and medical professions since their ancient beginnings.56 In the 1930s,
approximately 60% of all medications were compounded by
pharmacists.57 As times changed and major pharmaceutical companies
in the United States began mass producing most medications, the art of
compounding steeply declined.58 In the mid-twentieth century,
pharmacists moved from being the makers of medicine to mere
dispensers of mass-produced products.59 But as the twentieth century
progressed, medical professionals have revived the compounding
movement, realizing the benefits that custom medications afford their
patients.60 In 2019 alone, the drug compounding industry had an
estimated U.S. market size of $8.9 billion.61
Custom compounded medications provide patients with a variety
of benefits they cannot obtain by mass-produced pharmaceuticals. One
of the most important, and most interesting, benefits is that
compounded medications can allow patients access to medications that
large pharmaceutical manufacturers have discontinued.62 Patients who
still need this discontinued medication can receive it through
compounding, where a pharmacist or physician can recreate the
medication using pharmaceutical ingredients and the latest research.63
This process allows patients who need vital medicines to receive them
continuously, regardless of the pharmaceutical industry’s red tape.
Additionally, compounded medications allow patients with allergies to
obtain the benefits of the medication without the unwanted side
effects.64 For example, if a patient is allergic to dyes, gluten, or lactose,
a physician or pharmacist could make the medication without the
offensive ingredient. This practice allows patients the ability to take
56 History and Evolution of Compounding, MEDISCA (last visited Dec. 12, 2020),
https://www.medisca.com/compounding/history-and-evolution.
57 Frequently Asked Questions about Pharmaceutical Compounding, Doug’s
Compounding Pharmacy (last visited Dec. 12, 2020), https://www.dougsrx.com/faq/.
58 History
and
Evolution
of
Compounding,
MEDISCA
(2019),
https://www.medisca.com/compounding/history-and-evolution.
59 Id.
60 Id.
61 Greg Levine, Joshua Oyster & Rebecca Williams, Outsourcing Facilities Face Rising
Drug
Compounding
Risks,
LAW
360
(Sept.
18,
2019),
https://www.law360.com/articles/1199983/outsourcing-facilities-face-rising-drugcompounding-risks.
62 Frequently Asked Questions, supra note 18.
63 Frequently Asked Questions, supra note 18.
64 Frequently Asked Questions, supra note 18.
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necessary medications without the sometimes painful and bothersome
side effects.65 Customized compounded medications also allow for
changes in dosage and method of delivery in order to benefit specific
patients like children and the elderly, as previously described above.66
While there certainly are benefits to compounded medications,
there are a variety of risks associated with them.67 The FDA approves
and controls drugs manufactured by pharmaceutical companies and
dispensed by pharmacists.68 The Center for Drug Evaluation and
Research (“CDER”), a branch of the FDA, evaluates all new drugs before
they become available for use by consumers.69 The CDER drug approval
process requires a team of highly-trained physicians, chemists, and
pharmacologists to evaluate the clinical testing performed on a
particular drug.70 Simply put, this in-depth analysis assesses how a
medication seeks to treat a particular illness and ensures that the
intended benefits of the medication outweigh the potential risks.71 A
stamp of approval from CDER, and subsequently the FDA, allows
physicians and their patients peace of mind in knowing that the
prescribed medication is effective and safe for use.72
As stated before, the FDA itself does not regulate the approval
process of compounded medications.73 Therefore, the FDA cannot
verify the safety, effectiveness, and quality of compounded medications
as it does with manufactured drugs.74 Although the FDA has regulations
in place and frequently issues guidance documents regarding
compounded medications, the lesser oversight subjects consumers to a
heightened risk of unsafe formulations. For example, “[i]n 2001 and in
2006, FDA investigators found that [thirty percent] of compounded
drug samples they tested contained either too little or too much of the
active ingredient.”75 Additionally, unlike the flurry of regulations and
Patients with Allergies, supra note 27.
Heitman, supra note 22.
67 Jennifer Gudeman et. al, Potential Risks of Pharmacy Compounding, 13 DRUGS IN
R&D 1, 1-8 (Mar. 23, 2013), https://link.springer.com/article/10.1007%2Fs40268013-0005-9.
68 Development and Approval Process, U.S. FOOD & DRUG ADMIN. (2019),
https://www.fda.gov/drugs/development-approval-process-drugs.
69 Id.
70 Id.
71 Id.
72 Id.
73 Compounding and the FDA, supra note 1.
74 Compounding and the FDA, supra note 1.
75 Catherine Staes et. al., Description of Outbreaks of Healthcare Associated Infections
Related to Compounding Pharmacies 2000‐2012, AM. J. HEALTH SYS. PHARM (Aug. 1, 2014),
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3886339/.
65
66
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testing performed on manufactured medications, there are fewer safety
regulations regarding compounded medications. For example, there are
currently no state regulations that require pharmacists or physicians to
have specialized drug compounding training.76 It is concerning that
individuals tasked with mixing individualized medications are not
required to have any additional training regarding the drugs or the
compounding preparation. Lastly, because the FDA does not approve or
regulate compounded drugs, they do not require compounders to report
adverse events.77 This is particularly concerning because the FDA, and
consequently consumers, may never know of potentially serious issues
that exist in compounding pharmacies or physicians’ offices.
The most important illustration of these risks came in October
2012 when the United States experienced a serious fungal meningitis
outbreak that occurred as the result of contaminated compounded
drugs.78 Contaminated injectable methylprednisolone, a type of steroid
injection manufactured by New England Compounding Center (“NECC”)
in Framingham, Massachusetts, caused this outbreak.79
This
contaminated compounded drug affected patients in over nineteen
states across the country.80 Estimates suggest that this single
compounding pharmacy put over thirteen thousand people at risk.81
The Center for Disease Control and Prevention (“CDC”) reports that over
750 patients developed serious illnesses including meningitis, stroke,
joint infections, and other central nervous system infections. Sixty-four
of those patients died as a result of their injuries.82 Additionally, those
who survived the incident still suffer consequences, enduring years of
medical treatments and devastating pain.83
Although this outbreak is the most well-known incident,
compounded drugs caused eleven other infectious incidents between
2000 and 2012.84 These prior cases involved 207 patient injuries

Frequently Asked Questions, supra note 18.
Compounding and the FDA, supra note 1.
78 Staes, supra note 75, at 2.
79 Staes, supra note 75, at 2.
80 Staes, supra note 75, at 2.
81 DeNoon, supra note 41.
82 How the NECC Case Changed Compounding Pharmacy, MJH LIFE SCIENCES (June 14,
2017), [hereinafter NECC], https://www.drugtopics.com/latest/how-necc-casechanged-compounding-pharmacy; Sydney Lupkin, 5 Things We Didn’t Know About the
Fungal Outbreak Last Year, ABC NEWS (last visited Jan. 16, 2020),
https://abcnews.go.com/Health/things-fungal-outbreak-year/story?id=20661674.
83 Id.
84 Staes, supra note 75 at 1.
76
77

DIGORI (DO NOT DELETE)

2021]

2/2/2021 9:18 AM

COMMENT

221

resulting in seventeen deaths85 and an overall fatality rate of 8.2%.86
Including the 2012 outbreak, thirteen different drugs produced at
twelve different compounding pharmacies in ten different states caused
these incidents.87 Additionally, authorities only discovered ten of the
outbreaks after a “cluster of case-patients from a common hospital or
clinic presented with similar clinical characteristics to a common
setting.”88 This means that compounding pharmacies, free from
requirements to report adverse events like outbreaks, could have been
distributing dangerous contaminated drugs for an extended period of
time.89 Lastly, an investigation into one of these compounding facilities,
performed only after several patients fell ill, found a second
contaminated drug with the potential to harm the public.90
D. Who Regulates Drug Compounding?
The regulations surrounding drug compounding are complex in
nature, come from a variety of sources, and lack clarity.91 Although all
compounded drugs pose the same risks, different regulations apply to
compounding performed in different settings.92 According to the FDA,
“quality requirements for compounded drugs differ depending on the
setting where compounding occurs.”93 Additionally, because the
regulations vary so much, they are particularly hard to enforce, creating
more potential for harm to consumers.94 Although the FDA does not
follow a strict approval process for compounded drugs in the same way
that they do manufactured drugs, it still has set standards.95 State
regulatory agencies, whose practices can vary widely from state to state,
then enforce these federal regulations.96 This section will summarize
the regulations.

Staes, supra note 75, at 1.
Staes, supra note 75, at 1.
87 Staes, supra note 75, at 8-9.
88 Staes, supra note 75, at 9.
89 See generally Staes, supra note 75.
90 Staes, supra note 75, at 10.
91 Compounding Confusion: Uncertainty Swirls in Compound Pharmacy Regulation,
QUARLES & BRADY, LLP (Aug. 7, 2017), https://www.quarles.com/news/compoundingconfusion-uncertainty-swirls-in-compound-pharmacy-regulation/.
92 Id.
93 Compounding and the FDA, supra note 1, at 3.
94 Compounding and the FDA, supra note 1, at 3.
95 Compounding and the FDA, supra note 1, at 2-3.
96 See State Regulation of Compounding Pharmacies, supra note 38.
85
86
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1. Federal Regulations
In November of 2013, Congress passed bipartisan legislation called
the Drug Quality and Security Act (DQSA), which sought to create more
oversight and accountability in the making of compounded
medications.97 This legislation was a direct response to the 2012
meningitis outbreak that resulted from unsafe compounded
medications.98 DQSA clearly identified the two types of compounders—
”traditional” and “non-traditional” compounders.99
Traditional
compounders are pharmacies or physicians who prepare medications
in light of a specific patient’s needs via an individual prescription.100
Section 503A of the FDCA governs these compounders.101 Nontraditional compounders, enumerated for the first time in the DQSA, are
known as outsourcing facilities.102 Essentially, these facilities are
companies who produce inventory of commonly compounded drugs,
created without a patient-specific prescription, and sell them to
physicians for office use.103 Section 503B of the FDCA governs these
outsourcing facilities.104 The FDA solely regulates these facilities and
these facilities are not subject to the same state-level regulations as
traditional compounders, as will be explained below.105
The Food and Drug Administration Modernization Act of 1997
added Section 503A to the FDCA.106 Section 503A sets forth the
conditions that must be satisfied for drug products compounded by a
licensed pharmacist or physician in order to be exempt from the
following three sections of the FDCA.107 Compounding pharmacies do
not have to comply with: (1) Section 501(a)(2)(B) concerning current
good manufacturing practice; (2) Section 502(f)(1) concerning the
labeling of drugs with adequate directions for use; and (3) Section 505
concerning the approval of drugs under new drug applications.108
Drug Quality and Security Act, H.R. 3204, 113th Cong. (2013-2014).
See Compounding Laws and Policies, U.S. FOOD AND DRUG ADMIN. (last visited Dec.12,
2020), https://www.fda.gov/drugs/human-drug-compounding/compounding-lawsand-policies.
99 Drug Quality and Security Act, H.R. 3204, 113th Cong. (2013-2014).
100 Id.; See Frequently Asked Questions, supra note 18.
101 See Frequently Asked Questions, supra note 18.
102 H.R. 3204.
103 Id.
104 Id.
105 Id.
106 Pharmacy Compounding of Human Drug Products Under Section 503A of the
Federal Food, Drug, and Cosmetic Act, U.S. FOOD AND DRUG ADMIN. (June 2016),
https://www.fda.gov/media/94393/download.
107 Id.
108 Id.
97
98
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In contrast, Section 503B governs outsourcing facilities that
compound medications that are sold to healthcare facilities for in-office
use.109 The FDA is the sole regulator of these outsourcing facilities; thus,
all outsourcing facilities are required to register with the FDA.110
Section 503B also requires that these outsourcing facilities comply with
USP Sections 795 and 797, as well as with the CGMP.111 This extra
compliance with the CGMP makes the standards stricter under Section
503B than for compounding pharmacies under Section 503A.112
Additionally, these regulations force outsourcing facilities to follow
DQSA labeling requirements while compounding pharmacies under
Section 503A are not required to follow these same regulations. Hence,
drugs compounded at outsourcing facilities under more regulations will
likely have higher indicia of safety than those compounded at traditional
facilities regulated under Section 503A.
Since the deadly meningitis outbreak in 2012, the FDA has
provided numerous guidance documents, including priorities plans
highlighting their drug compounding initiatives.113 In 2018, the FDA
shared a Compounding Priorities Plan that emphasized the
administration’s key priorities for the coming years.114 In its 2018
regulations, the FDA stated that one of its goals was having more
compounding pharmacies register as 503B facilities because they are
subject to higher quality standards and better oversight than any other
compounding facility.115
2. State Regulations
At the same time that federal regulations were being debated to
ensure that a public health crisis similar to the meningitis outbreak
would not occur again, many states began to re-examine their drug
compounding regulations. Although the specific duties and functions
may vary slightly from state to state, each state has a collection of
professional regulatory boards that serve the public by governing the
licensing and practicing of individuals within a particular occupation.116
See Understanding 503A vs. 503B, supra note 52.
See Understanding 503A vs. 503B, supra note 52.
111 Understanding 503A vs. 503B, supra note 52.
112 See Understanding 503A vs. 503B, supra note 52.
113 See e.g., Compounding and the FDA, supra note 1.
114 2018 Compounding Priorities Plan, U.S. FOOD AND DRUG ADMIN. (June 21, 2018),
https://www.fda.gov/drugs/human-drug-compounding/2018-compounding-policypriorities-plan.
115 Id.
116 See id.; See What is the Role of the Regulatory Board in Credentialing Programs?,
PROFESSIONAL
TESTING,
INC.
(2006),
109
110
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A regulatory board is usually comprised of various members of the
profession as well as members of the general public who have a
significant interest in the functioning of the board.117 These boards
create and enforce detailed licensing requirements which help
safeguard the public by ensuring that the individuals in a specific
profession have the necessary education and training.118 Additionally,
these boards ensure that the licensed professionals act in compliance
with the specific rules and regulations put in place by that board.119
Most boards have a detailed disciplinary process should they find,
usually via a complaint process, that a member is not acting in
accordance with their regulations.120 The board has the power to
suspend, revoke, or deny licensure to an individual who it deems
noncompliant with its regulations.121
State pharmacy boards are responsible for licensing pharmacists
practicing within their state.122 More specifically, they are responsible
for enforcing regulations regarding compounding done by pharmacists
in pharmacies.123
While the FDA oversees pharmaceutical
manufacturing, each state has their own specific regulations regarding
compounding and their own enforcement procedures. New Jersey’s
specific requirements are codified in the regulations and contain
standards for pharmacy compounding including storage,
recordkeeping, and safety protocols.124
In contrast, state medical boards are responsible for the licensing
and regulating of physicians within a particular state.125 Their main goal
is to assure the public that the physicians licensed in their state are, not
only qualified, but also provide patients with the highest standard of

https://www.proftesting.com/test_topics/pdfs/regulatory_boards.pdf
[hereinafter
Role of the Regulatory Board].
117 See e.g., Board Members, The New Jersey Board of Pharmacy (last visited Jan. 16,
2019), https://www.njconsumeraffairs.gov/phar/Pages/members.aspx.
118 See Role of the Regulatory Board, supra note 116.
119 See Role of the Regulatory Board, supra note 116.
120 See Role of the Regulatory Board, supra note 116; see also Ike Devji, What You Need
To Know About Medical Board Complaints, PHYSICIAN’S PRACTICE (Aug. 28, 2019),
https://www.physicianspractice.com/view/what-you-need-know-about-medicalboard-complaints.
121 See Role of the Regulatory Board, supra note 116; see also Ike Devji, What You Need
To Know About Medical Board Complaints, PHYSICIAN’S PRACTICE (Aug. 28, 2019),
https://www.physicianspractice.com/view/what-you-need-know-about-medicalboard-complaints
122 See State Regulation of Compounding Pharmacies, supra note 38.
123 See State Regulation of Compounding Pharmacies, supra note 38.
124 See State Regulation of Compounding Pharmacies, supra note 38.
125 See Role of the Regulatory Board, supra note 116.
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care.126 Because the compounding of drugs can be performed by both
pharmacists and physicians alike, quality and safety control falls
directly upon these two regulating bodies and can often get lost in the
shuffle. While it is clear that boards of pharmacy have control over
pharmacists who compound drugs, they do not always have jurisdiction
over physicians who do so.127
Additionally, state medical boards are usually complaint-driven
agencies.128 This means that the board does not typically inspect or
examine a doctor’s office until a patient has filed a complaint against
them.129 Therefore, unsafe and hazardous compounding conditions are
only found after a patient suffers harm. This could create a dangerous
situation if a physician is compounding a large quantity of unsafe drugs.
The situation will only come to light and be remedied once an injured or
aggrieved party files a complaint with the board, which could ultimately
be too late.
In New Jersey, the Board of Pharmacy governs compounding done
by pharmacists in the state and sets out specific regulations that must
be followed in these compounding pharmacies.130 The state medical
board is silent, however, on regulating physician compounding.131
Therefore, only professional standards set by the profession itself
regulate physicians who compound in New Jersey.132
III. ANALYSIS
A. Ohio as a Test State for Implementing Stricter Regulations
In order to decide what will best serve New Jersey, this comment
will first analyze the changes that were made to compounding
regulations in other states like Ohio. Then, this comment will propose a
pathway that New Jersey regulators can adopt in moving forward with
stricter regulations on physician in-office compounding. The strongest,
See Role of the Regulatory Board, supra note 116.
Rebecca Burke, Physician Compounding Comes Under Scrutiny, AHLA WEEKLY
(Jun. 1, 2018), https://www.powerslaw.com/wp-content/ uploads/ 2018/06/
Weekly_Burke.pdf.
128 John W. Rusher, How To Prevent, Respond To A Complaint To State Medical Board,
APP NEWS (last visited Jan. 16, 2020),
https://www.aappublications.org/news/2018/03/02/law030218.
129 Id.
130 N.J. ADMIN. CODE § 13:39-11 (2020); These specific regulations will not be
discussed in detail as they do not apply to physicians compounding in their offices.
These regulations are standard and in compliance with the FDA and USP standards for
compounding after 2013.
131 N.J. STAT. ANN. § 45:9 et seq.
132 Id.
126
127
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and most important argument will be that New Jersey should implement
stricter regulations on physicians that force them to take advantage of
503B outsourcing facilities. In doing so, residents will maintain access
to compounded drugs, and rest assured they are created in the safest
environments with the strictest regulations.
Ohio was one of the first states to pioneer changes to state-level
regulations involving drug compounding after federal-level changes to
the industry in 2013.133 Currently, Ohio has the strictest drug
compounding laws in the country; it serves as the prototype for other
states as they contemplate changes to their own drug compounding
regulations.134 In order to better oversee the process of drug
compounding in the most effective way, the Ohio Board of Pharmacy
oversees all compounding done by traditional compounders, including
physicians.135
As of April 1, 2017, the Ohio Board of Pharmacy requires that all
prescribers who possess compounded drugs obtain a license as a
terminal distributor of dangerous drugs (“TDDD”).136 Additionally,
those who engage in the compounding of dangerous drugs (i.e.
prescription drugs), must obtain this TDDD license as well.137 After
April 1, 2017, any facility possessing compounded drugs or engaging in
the compounding of drugs without complying with the TDDD licensing
requirements violates Ohio law.138 The TDDD licensing requirements
includes the completion of “a 17-page form, an annual $160.00 fee, and
an agreement to have the premises inspected at any time without
notice.”139
133 See Brett Coldiron, The Compounding Struggle Continues, MD EDGE (Oct. 23,
2018),
https://www.mdedge.com/dermatology/article/177795/businessmedicine/compounding-struggle-continues-write-now-help-your.
134 See id.
135 See National Reports Raise Questions, supra note 7 at 8.
136 OHIO REV. CODE. ANN. § 4729.541(c)-(d) (LexisNexis 2017); Terminal Distributor
Requirements for Prescribers Possessing Compounded Drugs or Engaging in Drug
Compounding,
STATE
OF
OHIO
BD.
OF
PHARM.
(Feb.
11,
2017),
https://www.pharmacy.ohio.gov/Documents/Licensing/TDDD/General/Terminal%2
0Distributor%20Requirements%20for%20Prescribers%20Possessing%20Compound
ed%20Drugs%20or%20Engaging%20in%20Drug%20Compounding.pdf.
137 Id.
138 Terminal Distributor Requirements for Prescribers Possessing Compounded Drugs
or Engaging in Drug Compounding, STATE OF OHIO BD. OF PHARM. (Feb. 11, 2017)
https://www.pharmacy.ohio.gov/Documents/Licensing/TDDD/General/Terminal%2
0Distributor%20Requirements%20for%20Prescribers%20Possessing%20Compound
ed%20Drugs%20or%20Engaging%20in%20Drug%20Compounding.pdf.
139 Elizabeth Muennich & Brett Coldiron, Barriers to Compounding in Physician
Offices: The Future Is Now, J. AM ACAD. DERMATOLOGY (Mar. 2019),
https://www.jaad.org/action/showPdf?pii=S0190-9622%2818%2932581-7.
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The new regulations define compounding broadly to encompass
almost any mixing of two or more prescription drugs; the regulations
also do not differentiate between sterile and non-sterile medications.140
Additionally, the regulations provide that compounded drugs used
within six hours of preparation must be prepared in a designated, clean
“medication area” by authorized personnel with proper hand
hygiene.141 Compounded drugs that are used more than six hours after
being prepared require a designated “clean room” with environmental
control devices and additional equipment which is limited to authorized
personnel whom have had additional training.142
B. Proposals for New Jersey
1. Using Ohio as a Guidepost for Flexible Regulations
and Incentivizing Outsourcing Facilities
Physicians in Ohio have had negative reactions and strongly
oppose the new regulations that were put in place in 2017.143 It is
important for New Jersey to recognize the Ohio medical communities’
feedback, and work to find a balance that works favorably for physicians
and consumers. Such attention should be paid because it will be crucial
to use Ohio’s regulations as a guidepost for designing New Jersey
regulations going forward.
The main complaint from physicians regarding Ohio’s regulations
is that they believe requiring all compounders to acquire a TDDD is too
strict.144 Additionally, physicians claim that the standards attached to
the TDDD license are unduly restrictive and unnecessary. These
standards also impose serious financial burdens on the physicians.145
New Jersey could certainly come up with a different licensing
See OHIO REV. CODE ANN. § 4729.01(c) (LexisNexis 2017).
See Terminal Distributor Requirements for Prescribers Possessing Compounded
Drugs or Engaging in Drug Compounding, STATE OF OHIO BD. OF PHARM. (Feb. 11, 2017)
https://www.pharmacy.ohio.gov/Documents/Licensing/TDDD/General/Terminal%2
0Distributor%20Requirements%20for%20Prescribers%20Possessing%20Compound
ed%20Drugs%20or%20Engaging%20in%20Drug%20Compounding.pdf.
142 Id.;
Cost of a Cleanroom per Square Foot, MERCART CLEANROOMS,
https://www.mecart-cleanrooms.com/cost-cleanroom-per-square-foot/. Necessitating
a “clean room” space would require physician compounders to create an entirely new
space where physicians could compound medications in line with the standards
promulgated in Ohio, which could be incredibly expensive. Clean rooms, for example,
may need to include certain ventilation systems, air pressure systems, fume hoods, and
separate areas for personnel to dress in gowns and other protective equipment. The cost
of implementing one of these rooms can range from $100 - $1000 per square foot.
143 See Coldiron, supra note 133.
144 See Coldiron, supra note 133.
145 See Coldiron, supra note 133133.
140
141
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requirement for compounding physicians that is less strict than a TDDD
license. It is in the best interests of the State to create an entirely new
licensing process for physicians altogether since there are little to no
regulation in this area of the law. Working with a hybrid committee, as
explained below, could allow regulators and physicians to come up with
an option that is less burdensome while still acting to protect patients
from potentially dangerous drugs. An intense study of the Ohio rules, as
well as a collaborative effort involving all interested parties, would
certainly make for the most efficient outcome. However, the result of
this process must increase safety for consumers of physician
compounded drugs in New Jersey.
One of the most innovative programs regarding compounding
regulations has been the creation of outsourcing facilities that are
regulated under Section 503B.146 As previously stated, these facilities
are able to produce mass quantities of commonly compounded drugs
These compounded
without patient-specific prescriptions.147
medications are then sold to physicians and other healthcare facilities
for in-office use.148 The outsourcing facilities are regulated under
stricter rules than Section 503A facilities because they must comply
with CGMP in addition to other USP regulations.149 These facilities are
required to register with the FDA, in addition to the state’s Boards of
Pharmacy, so they are subject to risk-based inspections by the FDA.150
All of these additional regulations indicate that drugs produced at these
facilities are likely to be safer for the consumer—the explicit goal the
FDA expressed in both its 2018 and 2019 compounding guidance
documents.151
New Jersey should incentivize the creation of outsourcing facilities
in our state because of the benefits mentioned above, including lower
risk to patients who use compounded medications. If New Jersey were
to adopt strict standards for compounding that are similar to Ohio’s,
physicians who use compounded medications to treat their patients
regularly, but not enough to necessitate compliance with tedious TDDD
requirements, would likely outsource their compounding needs. By
forcing physician compounders to either comply with stricter
regulations or utilize 503B outsourcing facilities, compounded drugs
will inevitably be subject to more regulations and, thus will be safer for
146
147
148
149
150
151

Shepherd, supra note 53, at 395-96.
Understanding 503A vs. 503B, supra note 52.
Understanding 503A vs. 503B, supra note 52.
Understanding 503A vs. 503B, supra note 52.
2018 Compounding Priorities Plan, supra note 114, at 1.
2018 Compounding Priorities Plan, supra note 114, at 1-3.
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consumers. Incentives like tax breaks or tax exemptions would
stimulate the creation of outsourcing facilities in New Jersey.152
Additionally, bringing these facilities into the state would create more
jobs and help to stimulate New Jersey’s economy.153
2. Giving the State Board of Pharmacy Jurisdiction Over
Physicians
New Jersey can help close the gap in legislation regarding
compounding pharmacies and physician in-office compounding by
granting the New Jersey Board of Pharmacy jurisdiction over physicians
who compound in their offices. Although this would create more work
for the New Jersey Board of Pharmacy, it would also create regulations
for the direct oversight of physicians who compound in their offices.
Ohio did this in 2017 and it has been met with some opposition, but that
controversy stems from the strictness of the regulations, not the fact
that the Ohio Board of Pharmacy has jurisdiction over physician inoffice compounding.
3. Creating a Hybrid Committee
Another important step that would help close the regulatory gap
between compounding pharmacies and physician in-office
compounding includes New Jersey establishing a hybrid committee
consisting of members of the New Jersey Board of Pharmacy and the
New Jersey Board of Medical Examiners. The committee could also, if
deemed necessary, include outside members of both professions who
have a significant interest in the regulations of compounding in general
as well as physician in-office compounding. This committee would
mainly serve an advisory role that would help guide regulatory changes
of compounded medications. Regulatory boards often form outside
committees in order to investigate in-depth issues that will affect the
board and all of its licensees. It is important that concerns surrounding
compounded medications be debated in the most collaborative way
possible in order to establish regulations that work for pharmacists,
physicians, and most importantly, the consumers.
Creating or changing regulations and legislation is a notoriously
lengthy process that necessitates careful consideration. For example, it
took almost a full year after the 2012 meningitis outbreak for new

152 Carl Davis, Tax Incentives: Costly for States, Drag on the Nation, INST. ON TAX’N AND
ECON.
POL’Y
(Aug.
12,
2013),
https://itep.org/wpcontent/uploads/taxincentiveeffectiveness.pdf.
153 See id.
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federal statutes to be passed regarding human drug compounding.154
Even today, seven years later, there is still a great amount of work to be
done. The hybrid committee, while not a perfect solution, would allow
an intense and necessary discussion of the issues surrounding physician
compounding and could educate the New Jersey Legislature and other
regulatory bodies who will ultimately have the final say in what the next
steps will be for New Jersey. Additionally, both regulatory boards have
an important stake in the issue and would benefit from working
together to efficiently establish guideposts in order to protect consumer
health. There can never be too much dialogue surrounding an
important issue, especially one that affects the health of so many New
Jersey residents.
C. Counterarguments
The potential for new restrictions on in-office compounding has
already been widely contested by physicians.155 Physicians claim that
new FDA guidance requiring their facilities to comply with the same
standards as compounding pharmacies would limit their ability to
provide vital care to their patients.156 Some physicians argue that
stricter restrictions would severely limit a physician’s ability to prepare
sterile drug products to administer to patients.157 Physicians claim that
the reduced access to care will increase risks for patients because there
will be fewer facilities providing theses sterile drugs.158 Additionally,
doctors claim that it would be extremely difficult for them to retrofit
their offices with the new equipment and “clean rooms” that Ohio’s
guidance requires.159
In order to comply with the potential
requirements, such as implementing designated clean rooms or a vent
hood, some offices would be required to make structural changes or find
new spaces to operate.160 Lastly, physicians argue that there is little to
no evidence demonstrating a significant patient risk to necessitate a
massive overhaul of the current in-office compounding system.161

2018 Compounding Priorities Plan, supra note 114, at 1.
Brett Coldiron, How To Explain Physician Compounding to Legis., MD EDGE (June
19,
2017),
https://www.mdedge.com/dermatology/article/140696/businessmedicine/how-explain-physician-compounding-legislators.
156 Coldiron, supra note 133.
157 See Coldiron, supra note 133.
158 Coldiron, supra note 133.
159 See Coldiron, supra note 133.
160 See Coldiron, supra note 133.
161 Coldiron, supra note 133.
154
155
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Dermatologists in Ohio have been some of the strongest voices in
In an article urging
opposition to this strict regulation.162
dermatologists and physicians nationwide to oppose such regulations,
the executives of Ohio Dermatological Association state that they are
“astounded by the intrusiveness of the Pharmacy board [sic].”163 They
go on to analyze the rules as applied to dermatology, stating that “mixing
any prescription drug into another vehicle, such as a liquid gel, or
ointment, for topical use is compounding” and “[w]hen you are
compounding a prescription, you are compounding a dangerous
drug.”164
Recently, dermatologists in Ohio have attempted to outline how
outrageous the TDDD licensing requirement is.165 Whilst urging other
dermatologists and compounding physicians across the country to
persuade their local legislators that the restrictive Ohio compounding
laws should not be enacted in other states, dermatologist Brett Coldiron
created a demonstration that he believes illustrates the unnecessary
restrictiveness of these regulations.166 He suggests when a doctor
quickly mixes epinephrine and bicarbonate in a syringe, a simple
procedure to treat skin cancer patients, will no longer be able to be
performed in Ohio without a TDDD license.167
Consumer health, however, should be the utmost priority for all
healthcare providers, including compounding pharmacists and
physicians who compound in their offices.
Although stricter
regulations, surprise office inspections, and additional registration
materials (such as a TDDD license) may take some initial getting used
to, it seems to be a small price to pay in order to ensure safer patient
care.
The physicians’ main argument is that having fewer physicians to
provide these vital medications will increase the costs to the consumer.
This rationale is, at best, flawed. The new category of outsourcing
facilities created by the FDA in 2013 could alleviate some of this
pressure. These facilities are able to create large quantities of
commonly compounded drugs and ship them to healthcare facilities
around the country.168 If the drugs were made in larger quantities and

162
163
164
165
166
167
168

Muennich, supra note 139.
Muennich, supra note 139 .
Muennich, supra note 139.
See Coldiron, supra note 155.
Coldiron, supra note 155.
Coldiron, supra note 155.
2018 Compounding Priorities Plan, supra note 114, at 2.
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in safer facilities that are regulated directly by the FDA, it would not only
be safer for the patient but also could lower prices.169
Additionally, allowing an exemption for physicians who conduct inoffice compounding that permits them to be non-compliant with FDA
regulations could inevitably create a loophole for compounding
operations under the guise of a physician170 Creative, profit-oriented
physicians could potentially circumvent the regulations put in place,
thereby weakening safeguards for patients across the country.171 A
loophole could certainly lead to another public health crisis, which could
be even worse than the 2012 meningitis outbreak that seriously harmed
thousands of people.172
IV. CONCLUSION
Drug compounding is a vital part of the medical landscape that
provides patients with the ability to obtain custom drugs that fit their
unique needs.173 Without drug compounding, there are many patients
who otherwise would be unable to obtain the medications necessary to
most effectively treat their illnesses.174 But, with all of the benefits
associated with compounded medications, there are also many risks as
well. The 2012 fungal meningitis outbreak sparked a wide range of
federal and state-wide changes in compounding regulations. The
outbreak also highlighted the many problems that existed within the
field currently, including physician in-office compounding.175 While
drug compounding will always involve some risk, there are certainly
ways for New Jersey to minimize them. It is in the state’s best interest
to take action to better regulate medical compounding to keep its
residents safe, especially that which is done in physicians’ offices.
New Jersey should first look to the Ohio regulations and use them
as a guidepost for their own regulations. The Ohio regulations have
undoubtedly made compounded drugs safer in the state but have also
faced much criticism from physicians in the state and around the
country, which should be taken into account as well. Finding a balance
between the strict Ohio regulations and the complete lack of regulations
in New Jersey is possible and crucial to protecting patients while still
allowing them access to their medications. New Jersey may also want to
169
170
171
172
173
174
175

See 2018 Compounding Priorities Plan, supra note 114, at 3.
Coldiron, supra note 155.
Coldiron, supra note 155.
NECC, supra note 82.
Compounding and the FDA, supra note 1.
Compounding and the FDA, supra note 1.
NECC, supra note 82 .
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experiment with other ways that can make compounded drugs safer,
including creating incentives for Section 503B outsourcing facilities to
operate in New Jersey. Forcing compounders into using more heavily
regulated outsourcing facilities, through stricter regulations for
physician compounders, will hopefully make drugs safer for the
consumer. Additionally, New Jersey should also consider giving the New
Jersey Board of Pharmacy jurisdiction over compounding physicians as
well as consider creating a hybrid committee with pharmacists,
physicians, and other members of the public in order to better
investigate this issue and all of the various solutions.
While physician opposition to these measures may be strong at
first, it is important to remember the backdrop that brought this issue
to the forefront of medicine in the first place. The 2012 meningitis
outbreak significantly affected nearly a thousand people, largely due to
the lack of regulations regarding compounded drugs.176 The protection
of the consumer should be the ultimate priority, and by putting stricter
regulations into effect, New Jersey will accomplish this.

176

Staes, supra note 75, at 1, 8-9.

